FDA OKs Sanofi Diabetes Drug In Newly Diagnosed Pediatric Patients

The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) to delay the decline of endogenous insulin production in children ages 8 to 17 recently diagnosed with stage 3 type 1 diabetes. The approval was based on Phase 3 PROTECT study data showing Tzield significantly slowed the decline in C-peptide levels versus placebo. This expands the drug's use following an earlier April 2026 label expansion for stage 2 disease patients as young as 1 year old.

06/15/2026, 1:15 PM • Benzinga

Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and Rising Disease Burden | DelveInsight

The osteoarthritis market is projected to grow at a 3% CAGR from 2026 to 2036, reaching USD 32.5 billion in 2025 across seven major markets. Growth is driven by an aging population, rising disease prevalence, and the launch of emerging therapies including LEVI-04, ZILOSUL, TissueGene-C, and AMZ001. Current treatment is dominated by opioids, but novel disease-modifying therapies and regenerative medicine approaches are expected to reshape the market landscape.

06/15/2026, 1:00 PM • GlobeNewswire

Communiqué de presse : Le Tzield de Sanofi approuvé aux États-Unis comme première thérapie modificatrice de la maladie pour les patients récemment diagnostiqués avec un diabète de type 1 au stade 3

The FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8-17 recently diagnosed with stage 3 type 1 diabetes, marking the first disease-modifying therapy for this indication. The approval is based on the phase 3 PROTECT trial demonstrating significant slowing of C-peptide decline. A confirmatory phase 3 BETA-PRESERVE study is currently underway.

06/12/2026, 6:09 PM • GlobeNewswire

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8-17 years recently diagnosed with stage 3 type 1 diabetes, making it the first disease-modifying therapy for this indication. The approval is based on the PROTECT phase 3 study showing significant slowing of C-peptide decline compared to placebo. A confirmatory BETA-PRESERVE study is ongoing.

06/12/2026, 6:09 PM • GlobeNewswire

Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor REX-8756 at the European Association of Allergy and Clinical Immunology (EAACI) and Revolutionizing Atopic Dermatitis (RAD) Congresses

Recludix Pharma announced preclinical data for REX-8756, an oral STAT6 inhibitor, demonstrating efficacy comparable to anti-IL-4/IL-13 antibody therapies in asthma and dermatitis models with a differentiated safety profile. The compound will be presented at EAACI and RAD congresses in June 2026. REX-8756 is currently in Phase 1 clinical trials under a partnership with Sanofi.

06/12/2026, 8:00 AM • GlobeNewswire

Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says

Sanofi discontinued its Phase 3 MOBILIZE study of riliprubart for CIDP patients due to failure to meet efficacy objectives. The setback highlights trial design challenges in CIDP studies and may strengthen Argenx's Vyvgart market position, which has demonstrated successful trial execution in the same indication.

06/11/2026, 9:09 AM • Benzinga

HR Tech 2026 Announces Initial Agenda: Focuses on Real-World AI Implementation, Skills, and Workforce Transformations

HR Tech 2026 conference (October 20-22 in Las Vegas) unveiled its agenda featuring sessions on AI implementation, skills development, and workforce transformation. Leading HR and talent executives from major companies including Amsted Industries, Cloudflare, IFF, Lumen, Sanofi, and TIAA will share practical strategies on job architecture, AI adoption, internal mobility, and HR technology readiness.

06/09/2026, 7:00 AM • GlobeNewswire

Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative

Sanofi and Owkin announced an expanded multi-year partnership to develop AI-powered biopharma agents for drug discovery and development. The agreement includes a five-year license for Owkin's K Pro AI Scientist platform, which combines multimodal patient data with biological AI systems. This builds on their existing 2021 collaboration focused on oncology and immunology research.

06/05/2026, 7:01 AM • Benzinga

Therini Bio Doses First Patients in Phase 1b Trial of Novel Anti-Inflammatory Therapy, THN391, for Diabetic Macular Edema

Therini Bio announced the first patient dosing in a Phase 1b trial of THN391, a novel anti-inflammatory monoclonal antibody targeting fibrin for diabetic macular edema treatment. The company also advanced THN622, a fibrin/VEGF bispecific antibody, as a potential new standard of care for retinal neurodegeneration. Initial trial data is expected in Q4 2026.

05/27/2026, 10:00 AM • GlobeNewswire

Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now?

Recursion Pharmaceuticals, an AI-focused biotech company, has hit a 52-week low despite partnerships with major pharmaceutical companies and Nvidia. While the company's AI-powered drug discovery platform shows promise and addresses a real problem in drug development costs and timelines, it lacks tangible clinical evidence. With no approved products and only early-stage pipeline candidates, the stock remains highly speculative and risky for most investors.

05/25/2026, 7:30 PM • The Motley Fool

1 Dirt Cheap Growth Stock to Buy Right Now

Sanofi is highlighted as an attractive growth stock in the healthcare sector trading at a low valuation. With a market cap of $100 billion, the company has a pipeline of 75+ projects including 34 in late-stage development. Despite strong Q1 2026 sales growth of 14% and Dupixent sales up 31%, the stock has declined 11% this year. Trading at a forward P/E of less than 9 (vs S&P 500 average of 22) and offering a 5.7% dividend yield, the article suggests it presents a good margin of safety for long-term investors.

05/18/2026, 4:30 PM • The Motley Fool

Diversify Your Portfolio With These European Dividend Stocks

The article highlights three European dividend stocks offering yields significantly higher than the S&P 500 average of 1.2%. Shell (SHEL) benefits from high oil prices and strategic transformation, Unilever (UL) demonstrates strong brand power with 43 consecutive years of dividend increases, and Sanofi (SNY) shows robust pharmaceutical growth with 30 consecutive years of dividend increases.

05/14/2026, 4:47 PM • Investing

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally

A hantavirus outbreak on a cruise ship sparked a biotech rally, but the article argues investors should avoid jumping in. The hantavirus is less contagious than COVID-19 and unlikely to become a global pandemic, limiting vaccine market potential. Even if it does spread widely, predicting which companies will succeed is nearly impossible, as demonstrated by COVID-19 vaccine developers. Better opportunities exist in established vaccine makers with strong pipelines or broad market index funds.

05/13/2026, 1:15 PM • The Motley Fool

Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight

The global colorectal cancer diagnostics and therapeutics market is projected to grow from USD 35 billion in 2025 to USD 73 billion by 2034 at a CAGR of ~9%. Growth is driven by rising colorectal cancer prevalence, increased screening awareness, advancements in non-invasive diagnostics (liquid biopsy, stool-based DNA tests), and emerging targeted therapies and immunotherapies. North America leads with 41% market share, while Asia-Pacific is the fastest-growing region.

05/13/2026, 1:00 PM • GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics announced that its CEO Arthur T. Sands will participate in fireside chats at the RBC Global Healthcare Conference (May 20, 2026) and Jefferies Global Healthcare Conference (June 3, 2026). The company is advancing targeted protein degradation medicines for oncology and autoimmune diseases, with clinical-stage programs including BTK degraders and CBL-B inhibitors, alongside partnerships with Sanofi, Gilead, and Pfizer.

05/13/2026, 7:00 AM • GlobeNewswire